Literature DB >> 8573079

Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.

C Aparicio1, B Dahlbäck.   

Abstract

Resistance to activated protein C (APC), which is the most prevalent pathogenetic risk factor of thrombosis, is linked to a single point-mutation in the factor V (FV) gene, which predicts replacement of Arg (R) at position 506 with a Gln (Q). This mutation modifies one of three APC-cleavage sites in the heavy chain of activated FV (FVa), suggesting that mutated FVa (FVa:Q506) is at least partially resistant to APC-mediated degradation. To elucidate the molecular mechanisms of APC-resistance and to investigate the functional properties of FV in APC resistance, FV:Q506 was purified from an individual with homozygosity for the Arg to Gln mutation. Intact and activated FV:Q506 were demonstrated to convey APC resistance to FV-deficient plasma. Thrombin- or factor Xa-activated FV:Q506 were found to be approx. 10-fold less sensitive to APC-mediated degradation than normal FVa, at both high and low phospholipid concentrations. The degradation pattern observed on Western blotting suggested that FVa:Q506 was not cleaved at position 506. However, it was slowly cleaved at Arg306, which explains the partial APC sensitivity of FVa:Q506. FV is initially activated during clotting and then rapidly inactivated in a process which depends on the integrity of the protein C anticoagulant system. During clotting of APC-resistant plasma, FV:Q506 was activated in a normal fashion, but then only partially inactivated. In conclusion, the reduced sensitivity of FVa:Q506 to APC-mediated degradation is the molecular basis for the life-long hypercoagulable state which constitutes a risk factor for thrombosis in APC-resistant individuals.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8573079      PMCID: PMC1216930          DOI: 10.1042/bj3130467

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  26 in total

1.  The activation of bovine coagulation factor X.

Authors:  J Jesty; Y Nemerson
Journal:  Methods Enzymol       Date:  1976       Impact factor: 1.600

Review 2.  The coagulation cascade: initiation, maintenance, and regulation.

Authors:  E W Davie; K Fujikawa; W Kisiel
Journal:  Biochemistry       Date:  1991-10-29       Impact factor: 3.162

3.  The interaction of a Ca2+-dependent monoclonal antibody with the protein C activation peptide region. Evidence for obligatory Ca2+ binding to both antigen and antibody.

Authors:  D J Stearns; S Kurosawa; P J Sims; N L Esmon; C T Esmon
Journal:  J Biol Chem       Date:  1988-01-15       Impact factor: 5.157

Review 4.  Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders.

Authors:  W H Kane; E W Davie
Journal:  Blood       Date:  1988-03       Impact factor: 22.113

5.  Inactivation of human coagulation factor V by activated protein C.

Authors:  K Suzuki; J Stenflo; B Dahlbäck; B Teodorsson
Journal:  J Biol Chem       Date:  1983-02-10       Impact factor: 5.157

6.  Characterization of functionally important domains in human vitamin K-dependent protein S using monoclonal antibodies.

Authors:  B Dahlbäck; B Hildebrand; J Malm
Journal:  J Biol Chem       Date:  1990-05-15       Impact factor: 5.157

7.  Familial protein S deficiency is associated with recurrent thrombosis.

Authors:  P C Comp; R R Nixon; M R Cooper; C T Esmon
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

8.  The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C.

Authors:  H M Bakker; G Tans; T Janssen-Claessen; M C Thomassen; H C Hemker; J H Griffin; J Rosing
Journal:  Eur J Biochem       Date:  1992-08-15

9.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.

Authors:  B Dahlbäck; M Carlsson; P J Svensson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

10.  Binding of anticoagulant vitamin K-dependent protein S to platelet-derived microparticles.

Authors:  B Dahlbäck; T Wiedmer; P J Sims
Journal:  Biochemistry       Date:  1992-12-29       Impact factor: 3.162

View more
  5 in total

1.  The effect of Arg306-->Ala and Arg506-->Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S.

Authors:  J O Egan; M Kalafatis; K G Mann
Journal:  Protein Sci       Date:  1997-09       Impact factor: 6.725

2.  Trombophilic screening for nonarteritic anterior ischemic optic neuropathy.

Authors:  Valeria Nagy; Zita Steiber; Lili Takacs; Gyorgy Vereb; Andras Berta; Zsuzsanna Bereczky; Gyorgy Pfliegler
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-04-15       Impact factor: 3.117

3.  Prevalence of resistence to activated protein C (APC-resistance) in blood donors in Kosovo.

Authors:  Ymer Mekaj; Bukurije Zhubi; Hakif Hoxha; Remzije Belegu; Agon Mekaj; Ermira Miftari; Mazllum Belegu
Journal:  Bosn J Basic Med Sci       Date:  2009-11       Impact factor: 3.363

4.  Near real-time immuno-optical sensor for diagnosing single point mutation: a model system: sensor for factor V Leiden diagnosis.

Authors:  Kyung A Kang; Yongjie Ren; Vivek R Sharma; Stephen C Peiper
Journal:  Biosens Bioelectron       Date:  2009-02-20       Impact factor: 10.618

5.  Structural investigation of the A domains of human blood coagulation factor V by molecular modeling.

Authors:  B O Villoutreix; B Dahlbäck
Journal:  Protein Sci       Date:  1998-06       Impact factor: 6.725

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.